DOCSLIB.ORG

Axillary Lymph Node Metastases Detection with 99Mtc-Sestamibi Scintimammography in Patients with Breast Cancer Undergoing Curative Surgery*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Axillary Lymph Node Metastases Detection with 99Mtc-Sestamibi Scintimammography in Patients with Breast Cancer Undergoing Curative Surgery* ANTICANCER RESEARCH 27: 2949-2952 (2007) Axillary Lymph Node Metastases Detection with 99mTc-sestamibi Scintimammography in Patients with Breast Cancer Undergoing Curative Surgery* FRANCO LUMACHI1, GUIDO FERRETTI2, MICHELE POVOLATO2, FRANCO BUI3, DIEGO CECCHIN3, MARIA CRISTINA MARZOLA3, PIETRO ZUCCHETTA3 and UMBERTO BASSO4 1Breast Surgery Unit, Department of Surgical and Gastroenterological Sciences, 3Nuclear Medicine Service, Department of Diagnostic Medical Sciences, University of Padua, School of Medicine, 35128 Padova; 2Nuclear Medicine Service, S.M. Misericordia Hospital, 33100 Udine; 4Division of Medical Oncology, Istituto Oncologico Veneto, IRCCS, 35128 Padova, Italy Abstract. Background: Axillary lymph node (AN) status is of the tumour (R=0.24, p<0.01) and number of positive the primary prognostic discriminant in patients with breast nodes (R=0.33, p<0.01). The sensitivity, specificity, positive cancer (BC). Although axillary dissection represents the predictive value, negative predictive value and accuracy of method of choice for obtaining such information, less SSM in detecting AN metastases were 81.4%, 91.0%, 84.2%, invasive procedures have been suggested. The aim of this 91.0% and 87.4%, respectively. The sensitivity was higher in study was to evaluate the usefulness of 99mTc-sestamibi patients with three or more positive nodes (27 out of 28, scintimammography (SSM) in detecting AN involvement in 96.4%), while in patients with two (n=25) or one (n=7) patients with confirmed primary BC undergoing surgery. positive nodes, the sensitivity decreased to 80% and 28.6%, Patients and Methods: A series of 159 consecutive women respectively. Conclusion: SSM may be useful in patients (median age 54 years, range 36-78 years) with confirmed BC undergoing surgery for BC when a preoperative assessment of undergoing curative surgery were enrolled in the study. Each axillary lymph node status is required. Unfortunately, the patient underwent SSM, from 4 to 12 days prior to surgery. sensitivity of SSM in detecting node metestases in patients According to the tumour staging, modified radical with BC is low when the number of involved nodes is two or mastectomy was performed in 41 (25.8%) patients, while 118 less. This suggests that other imaging techniques should be (74.2%) patients underwent breast conserving surgery with used is conjunction with SSM, with the aim of increasing dissection of the axilla. The results of SSM were compared both sensitivity and specificity. against the final histological evaluation of the axillary nodes. Results: The final pathology showed 33 (20.8%) pT1b, 90 Axillary lymph node (AN) status is the primary prognostic (56.6%) pT1c, and 36 (22.6%) pT2 breast carcinomas. The discriminant in patients with breast cancer (BC). greatest diameter of the tumour ranged from 8 to 30 mm Although axillary dissection represents the method of (median 16 mm). Sixty patients (37.7%) had axillary node choice for obtaining such information, less invasive metastases (N1), and 99 (60.3%) had negative nodes (N0). procedures have been suggested. Preoperative non- The age of the patients significantly correlated with both size surgical techniques include axillary ultrasonography (US) with or without US-guided fine-needle aspiration cytology (FNAC) or core-biopsy, fluorine-18-fluorodeoxyglucose (18-FDG) positron emission tomography (PET) and *Presented in part at the 12th European Cancer Conference 99m (ECCO 12), Copenhagen (Denmark), September 21-25, 2003. Tc-sestamibi scintimammography (SSM). The aim of this study was to evaluate the usefulness of Correspondence to: Prof. F. Lumachi, University of Padua, School SSM in detecting AN involvement in patients with of Medicine, Breast Surgery Unit, Department of Surgical and confirmed primary BC undergoing surgery. Gastroenterological Sciences, via Giustiniani 2, 35128 Padova, Italy. Tel: +39 049 821 1812, Fax: +39 049 656 145, e-mail: Patients and Methods [email protected] Study population. A series of 159 consecutive women (median age Key Words: Breast cancer, scintimammography, axillary node 54 years, range 36-78 years) with BC confirmed by FNAC, core metastases. biopsy or open biopsy undergoing curative surgery were enrolled 0250-7005/2007 $2.00+.40 2949 ANTICANCER RESEARCH 27: 2949-2952 (2007) Table I. Histological type of the tumour, and pathological staging at final Table II. Results of 99mTc-sestamibi scintimammography in detecting pathology. axillary node metastases. Characteristics N0 % N1 % Overall % TP FP TN FN Sensitivity Specificity PPV NPV Accuracy Overall patients 99 62.3% 60 37.7% 159 48 9 91 11 81.4% 91.0% 84.2% 91.0% 87.4% Histological type TP=true-positives, FP=false-positives, TN=true-negatives, FN=false- Infiltrating ductal 83 83.8% 56 93.3% 139 87.4% negatives, PPV=positive predictive value, NPV=negative predictive Infiltrating lobular 7 7.1% 1 1.7% 8 5.0% value. Medullary 3 3.0% 0 - 3 1.9% Other and mixed 6 6.1% 3 5.0% 9 5.7% Table III. Main differences between patients with true-positive and false- Pathological tumour stage negative scintimammorgaphy. pT1b 31 31.3% 2 3.3% 33 20.8% pT1c 66 66.7% 24 40.0% 90 56.6% Characteristics True-positives p-value False-negatives pT2 2 2.0% 34 56.7% 36 22.6% Number of patients 48 - 11 N0=number of patients with negative nodes, N1=number of patients Age (years) 58.8±7.7 <0.001 48.6±10.3 with involved nodes. Size of the tumour (mm) 21.2±4.5 0.06 18.2±5.4 Number of removed nodes 19.9±2.1 0.77 19.7±2.0 Number of positive nodes 3.0±1.2 <0.001 1.6±0.7 in the study. In patients with non-palpable masses the biopsy was pT2=21-50 mm; pN0=no lymph node metastases, pN1=metastases performed using a wire needle localization, under US or in at least one axillary node (5). stereotactic guidance. There were 44 (27.7%) premenopausal and A positive result of SSM identified the presence of one or more 115 (73.3%) post-menopausal women. metastatized AN. Sensitivity was defined as true-positives (TP)/TP Once they had given informed consent, each patient underwent + false-negatives (FN), specificity as true-negatives (TN)/TN + SSM, from 4 to 12 days prior to surgery. According to the tumour false-positives (FP), positive predictive values (PPV) as TP/(TP + staging, modified radical mastectomy was performed in 41 (25.8%) FP), negative predictive values (NPV) as TN/(TN + FN), and patients, while 118 (74.2%) patients underwent breast conserving accuracy as (TN + TP)/overall patients. surgery with AN dissection. The reported data are in part expressed as mean±standard The greatest diameter (size) of the tumour (pT) was deviation (SD). The Mann-Whitney U-test and the Pearson’s measured by the pathologist, and the final diagnosis was correlation coefficient (R) calculation were used for the obtained by routinely stained serial sections (1 mm of comparison of qualitative variables in the case of non-normal thickness). The results of SSM were compared against final distribution and to evaluate the linear relationship between pairs histological evaluation of AN. of variables, respectively. Comparisons between groups were performed using the Student’s t-test, when required. The 99mTc-sestamibi scintimammography. According to the procedure differences were considered significant at a p-value <0.05. guidelines suggested by The Society of Nuclear Medicine (SNM), a single dose (750 MBq) of 99mTc-sestamibi (methoxyiso- Results butylisonitrile) was injected in the arm contralateral to the side of the lesion (1). A triple head gamma camera (Philips Irix) equipped with a parallel-hole low-energy high-resolution collimator The size of the tumours ranged from 8 mm to 30 mm (resolution 7.5 mm at 10 cm), a 140 keV (10% window) energy (median 16 mm). Table I reports the histological type of the setting and a 256x256 matrix was used. tumours, and the pathological staging at final pathology. To improve the visualization of the axilla, patients were in prone Sixty patients (37.7%) had axillary node metastases (N1) position, with arms raised above the head, and the images were acquired 5-10 min after intravenous injection of the radio- and 99 (60.3%) had negative nodes (N0). The average pharmaceutical (2). number of removed nodes was 19.9±2.1 and the mean Planar (prone lateral, anterior and posterior oblique) images number of positive nodes was 2.7±1.2. combined with SPECT (128 x 128 matrix, 64 steps, 30 sec/step, The age of the patients significantly correlated with both size 180Æ acquisition) images were obtained. A focal uptake of the of the tumour (R=0.24, F=9.55, p=0.002) and number of 99m Tc-sestamibi, and a mass-to-background ratio of more than 1.4 positive nodes (R=0.33, F=7.11, p<0.009). As expected, there was considered as a positive result, as previously reported (3, 4). was a direct relationship (R=0.31, F=6.08, p=0.016) between Definitions and statistical analysis. The tumours were classified the size of the tumour and the number of positive nodes. according to the TNM classification: pT1b=6-10 mm in size The sensitivity, specificity, PPV, NPV, and accuracy of (greatest diameter measured by the pathologist), pT1c=11-20 mm, SSM in detecting AN metastases are reported in Table II. 2950 Lumachi et al: Axillary Scintimammography in Breast Cancer Patients with false-negative SSM were significantly (p<0.01) Acknowledgements younger than those in whom the imaging technique correctly detected involved AN (Table III). Moreover, the The authors are grateful to Dr. Annamaria Grigio and Miss number of removed AN did not differ (p=NS) between Federica De Lotto for help in writing the manuscript and for patients with true-positive and false-negative SSM, while the reviewing the English.
Load more

Recommended publications
  • Epilepsy & Seizure
    Epilepsy & Seizure Journal of Japan Epilepsy Society Vol.4 No.1 (2011) pp.15-25 Original Article Usefulness of 123I-iomazenil SPECT for childhood focal epilepsies 1) 1) 1) 1) Kentaro Okamoto, MD , Hirokazu Oguni, MD , Yoshiko Hirano, MD , Makiko Osawa, MD 1Department of Pediatrics, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan Key words: focal epilepsy, children, 123I-iomazenil SPECT, epileptic foci Published online July 29, 2011 Abstract Purpose: We investigated the usefulness of obtained from visualization of IMZ-SPECT 123I-iomazenil (IMZ-) SPECT to detect epilep- images and those speculated based on a com- tic foci in children with symptomatic focal bination of clinical manifestations, EEG find- epilepsy (SFE). ings, and brain MRI. We then verified the Subjects: 21 children with SFE who under- concordance of the results between the two went IMZ-SPECT to identify the epileptic fo- methods. cus were studied. Results: There was concordance in both later- Methods: We retrospectively compared the alization and localization in 9/12 patients with localization and lateralization of epileptic foci temporal lobe epilepsy (75%), in 2/5 patients Correspondence to: Hirokazu Oguni, MD, Department of Pediatrics, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162, Japan Tel. 81-3-3353-8111, Fax. 81-3-5269-7338, [email protected] 15 Kentaro Okamoto, et al. IMZ-SPECT for childhood epilepsy with frontal lobe epilepsy (40%), and in 2/4 interictal/ictal cerebral blood flow single pho- patients with parieto-occipital lobe epilepsy ton emission computed tomography (SPECT) (50%).
    [Show full text]
  • Imaging in Parkinson's Disease
    Clinical Medicine 2016 Vol 16, No 4: 371–5 CME MOVEMENT DISORDERS I m a g i n g i n P a r k i n s o n ’ s d i s e a s e Authors: G e n n a r o P a g a n o , A F l a v i a N i c c o l i n i B a n d M a r i o s P o l i t i s C The clinical presentation of Parkinson’s disease (PD) Abnormal intra-neuronal (Lewy bodies) and intra-neuritic is heterogeneous and overlaps with other conditions, (Lewy neurites) deposits of fibrillary aggregates are currently including the parkinsonian variant of multiple system considered the key neuropathological alterations in PD. atrophy (MSA-P), progressive supranuclear palsy (PSP) and The majority of these aggregates, mainly composed of alpha essential tremor. Imaging of the brain in patients with (α)−synuclein, are located at presynaptic level and impair ABSTRACT parkinsonism has the ability to increase the accuracy of axonal trafficking, resulting in a series of noxious events that differential diagnosis. Magnetic resonance imaging (MRI), cause neuronal damage to the substantia nigra pars compacta single photon emission computed tomography (SPECT) and with a subsequent dopaminergic denervation of the striatum. positron emission tomography (PET) allow brain imaging The cardinal motor features of PD (bradykinesia and rigidity, of structural, functional and molecular changes in vivo in with or without resting tremor) manifest after a substantial patients with PD. Structural MRI is useful to differentiate denervation of substantia nigra, which is associated with about PD from secondary and atypical forms of parkinsonism.
    [Show full text]
  • Surgical Options for Breast Cancer
    The Breast Center Smilow Cancer Hospital 20 York Street, North Pavilion New Haven, CT 06510 Phone: (203) 200-2328 Fax: (203) 200-2075 SURGICAL OPTIONS There are a number of surgical procedures available today for the treatment of breast cancer. You will likely have a choice and will need to make your own decision, in consultation with your specific surgeon, about the best option for you. We offer you a choice because the research on the treatment of breast cancer has clearly shown that the cure and survival rates are the same regardless of what you choose. The choices can be divided into breast conserving options (i.e. lumpectomy or partial mastectomy) or breast removing options (mastectomy). A procedure to evaluate your armpit (axillary) lymph nodes will likely occur at the same time as your breast surgery. This is done to help determine the likelihood that cells from your breast cancer have left the breast and spread (metastasized) to another more dangerous location. This information will be used to help decide about your need for chemotherapy or hormone blocking drugs after surgery. PARTIAL MASTECTOMY (LUMPECTOMY) A partial mastectomy involves removing the cancer from your breast with a rim, or margin, of normal breast tissue. This allows the healthy noncancerous part of your breast to be preserved, and usually will not alter the sensation of the nipple. The benefit of this surgical choice is that it often preserves the cosmetics of the breast. Your surgeon will make a decision about the volume of tissue that needs removal in order to maximize the chance of clear margins as confirmed by our pathologist.
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments
    Journal of Personalized Medicine Review Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments Atia Samim 1,2, Godelieve A.M. Tytgat 1, Gitta Bleeker 3, Sylvia T.M. Wenker 1,2, Kristell L.S. Chatalic 1,2, Alex J. Poot 1,2, Nelleke Tolboom 1,2, Max M. van Noesel 1 , Marnix G.E.H. Lam 2 and Bart de Keizer 1,2,* 1 Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands; [email protected] (A.S.); [email protected] (G.A.M.T.); [email protected] (S.T.M.W.); [email protected] (K.L.S.C.); [email protected] (A.J.P.); [email protected] (N.T.); [email protected] (M.M.v.N.) 2 Department of Radiology and Nuclear Medicine, University Medical Center Utrecht/Wilhelmina Children’s Hospital, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; [email protected] 3 Department of Radiology and Nuclear Medicine, Northwest Clinics, Wilhelminalaan 12, 1815 JD Alkmaar, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +31-887-571-794 Abstract: Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis. During the past decades, Citation: Samim, A.; Tytgat, G.A.M.; nuclear medicine has been essential for the staging and response assessment of neuroblastoma. 123 123 Bleeker, G.; Wenker, S.T.M.; Currently, the standard nuclear imaging technique is meta-[ I]iodobenzylguanidine ([ I]mIBG) Chatalic, K.L.S.; Poot, A.J.; whole-body scintigraphy, usually combined with single-photon emission computed tomography Tolboom, N.; van Noesel, M.M.; with computed tomography (SPECT-CT).
    [Show full text]
  • (18F-FDG) Uptake for PET/CT in Normal Organs
    www.nature.com/scientificreports OPEN Efects of blood glucose level on 18F fuorodeoxyglucose (18F- FDG) uptake for PET/CT in normal Received: 24 October 2017 Accepted: 18 January 2018 organs: an analysis on 5623 Published: xx xx xxxx patients Clarice Sprinz1,2, Matheus Zanon 3,4, Stephan Altmayer3,4, Guilherme Watte 3, Klaus Irion 5, Edson Marchiori 6 & Bruno Hochhegger 2,3,4 Our purpose was to evaluate the efect of glycemia on 18F-FDG uptake in normal organs of interest. The infuences of other confounding factors, such as body mass index (BMI), diabetes, age, and sex, on the relationships between glycemia and organ-specifc standardized uptake values (SUVs) were also investigated. We retrospectively identifed 5623 consecutive patients who had undergone clinical PET/ CT for oncological indications. Patients were stratifed into groups based on glucose levels, measured immediately before 18F-FDG injection. Diferences in mean SUVmax values among glycemic ranges were clinically signifcant only when >10% variation was observed. The brain was the only organ that presented a signifcant inverse relationship between SUVmax and glycemia (p < 0.001), even after controlling for diabetic status. No such diference was observed for the liver or lung. After adjustment for sex, age, and BMI, the association of glycemia with SUVmax was signifcant for the brain and liver, but not for the lung. In conclusion, the brain was the only organ analyzed showing a clinically signifcant relationship to glycemia after adjustment for potentially confounding variables. The lung was least afected by the variables in our model, and may serve as an alternative background tissue to the liver.
    [Show full text]
  • Initial Clinical Comparison of 18F-Florbetapir and 18F-FDG PET in Patients with Alzheimer Disease and Controls
    Journal of Nuclear Medicine, published on May 10, 2012 as doi:10.2967/jnumed.111.099606 Initial Clinical Comparison of 18F-Florbetapir and 18F-FDG PET in Patients with Alzheimer Disease and Controls Andrew B. Newberg1, Steven E. Arnold2, Nancy Wintering1, Barry W. Rovner1, and Abass Alavi2 1Thomas Jefferson University and Hospital, Philadelphia, Pennsylvania; and 2University of Pennsylvania, Philadelphia, Pennsylvania The purpose of this study was to determine how clinical inter- Alzheimer disease (AD) is a brain disorder of older pretations of the 18F-amyloid tracer florbetapir compares diagnos- adults, with symptoms of progressive decline in memory 18 tically with F-FDG PET when evaluating patients with Alzheimer and other cognitive functions. A definitive diagnosis of AD disease (AD) and controls. Methods: Nineteen patients with a clin- ical diagnosis of AD and 21 elderly controls were evaluated with can be established only by demonstrating the presence of both 18F-florbetapir and 18F-FDG PET scans. Scans were inter- abundant senile plaques and neurofibrillary tangles in post- preted together by 2 expert readers masked to any case informa- mortem brain sections (1,2). During life, most patients are tion and were assessed for tracer binding patterns consistent with diagnosed by clinical criteria that imperfectly track with AD. The criteria for interpreting the 18F-florbetapir scan as positive postmortem pathologic findings. The criteria for the diagno- for AD was the presence of binding in the cortical regions relative to sis of AD were defined by the Working Group of the Na- the cerebellum. 18F-FDG PET scans were interpreted as positive if they displayed the classic pattern of hypometabolism in the tem- tional Institute of Neurologic and Communicative Disorders poroparietal regions.
    [Show full text]
  • Amyloid and Tau Signatures of Brain Metabolic Decline in Preclinical Alzheimer's Disease
    European Journal of Nuclear Medicine and Molecular Imaging https://doi.org/10.1007/s00259-018-3933-3 ORIGINAL ARTICLE Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease Tharick A. Pascoal1 & Sulantha Mathotaarachchi1 & Monica Shin1 & Ah Yeon Park2 & Sara Mohades1 & Andrea L. Benedet1 & Min Su Kang1 & Gassan Massarweh3 & Jean-Paul Soucy3,4 & Serge Gauthier5 & Pedro Rosa-Neto 1,3,5,6 & for the Alzheimer’s Disease Neuroimaging Initiative Received: 12 September 2017 /Accepted: 2 January 2018 # The Author(s) 2018. This article is an open access publication Abstract Purpose We aimed to determine the amyloid (Aβ) and tau biomarker levels associated with imminent Alzheimer’s disease (AD) - related metabolic decline in cognitively normal individuals. Methods A threshold analysis was performed in 120 cognitively normal elderly individuals by modelling 2-year declines in brain glucose metabolism measured with [18F]fluorodeoxyglucose ([18F]FDG) as a function of [18F]florbetapir Aβ positron emission tomography (PET) and cerebrospinal fluid phosphorylated tau biomarker thresholds. Additionally, using a novel voxel-wise analytical framework, we determined the sample sizes needed to test an estimated 25% drugeffect with 80% of power on changes in FDG uptake over 2 years at every brain voxel. Results The combination of [18F]florbetapir standardized uptake value ratios and phosphorylated-tau levels more than one standard deviation higher than their respective thresholds for biomarker abnormality was the best predictor of metabolic decline in individuals with preclinical AD. We also found that a clinical trial using these thresholds would require as few as 100 individuals to test a 25% drug effect on AD-related metabolic decline over 2 years.
    [Show full text]
  • Lumpectomy/Mastectomy Patient/Family Education
    LUMPECTOMY/MASTECTOMY PATIENT/FAMILY EDUCATION Being diagnosed with breast cancer can be emotionally challenging. It is important to learn as much as possible about your cancer and the available treatments. More than one type of treatment is commonly recommended for breast cancer. Each woman’s situation is unique and which treatment or treatments that will be recommended is based on tumor characteristics, stage of disease and patient preference. Surgery to remove the cancer is an effective way to control breast cancer. The purpose of this educational material is to: increase the patient’s and loved ones’ knowledge about lumpectomy and mastectomy to treat breast cancer; reduce anxiety about the surgery; prevent post-operative complications; and to facilitate physical and emotional adjustment after breast surgery. THE BASICS There are three primary goals of breast cancer surgery: 1. To remove a cancerous tumor or other abnormal area from the breast and enough surrounding breast tissue to leave a “margin of safety” around the tumor or affected area. 2. To remove lymph nodes from the armpit area (axilla) to check for possible spread of cancer (metastasis) or remove lymph nodes that are already known to contain cancer. 3. Sometimes one or both breasts are removed to prevent breast cancer if a woman is at especially high risk for the disease. Breast cancer surgery can be done before or after chemotherapy (if chemotherapy is recommended). Radiation therapy and hormonal therapy (if recommended) are typically done after surgery. There are several types of breast surgery. The type of surgery best suited for a specific woman depends on the type of breast disease, the size and location of the breast disease/tumor(s) in the breast, and the personal preference of the patient.
    [Show full text]
  • Advances in Breast Reconstruction After Lumpectomy and Mastectomy
    ADVANCES IN BREAST RECONSTRUCTION AFTER LUMPECTOMY AND MASTECTOMY Breast cancer has been described as far back as 1600 B.C. in the papyrus writings of the ancient Egyptians. Galen later theorized that the cancer was due to a collection “of black bile” inside the breast. Virchow proposed this so-called “tumor” originated from the epithelium and spread outward in all directions. The American surgeon William Halsted supported the theory that breast cancer began as a “regional” phenomenon, before it spread distantly. And in 1882 he first performed the first Radical Mastectomy, which involved removal of the entire breast, the lymph nodes in the area, and the underlying pectoralis chest wall muscles. As you can imagine, this led to a very disfiguring appearance, but Halsted was able to achieve a 5-year cure rate of 40% which was unheard of at the time. Because of Halsted’s principles, breast reconstruction was really never an option since it was considered a “violation of the local control of the disease.” Halsted warned surgeons not to perform plastic operations at the mastectomy site because he believed it could hide local recurrence and “may sacrifice his patient to disease.” Therefore, many of the initial attempts at breast reconstruction took place in Europe. EARLY BREAST RECONSTRUCTION Breast reconstruction itself dates back to the 1800s, with the initial attempt taking place in 1895 by the German surgeon, Vincent Czerny. He reported the case of a 41 year old singer who required a mastectomy for a fibroadenoma and chronic infections. He reported that “since both breasts were very well developed” she would have “an unpleasant asymmetry” after removal of one breast, which would have “hindered her stage activity”.
    [Show full text]
  • Consensus Guideline on the Management of the Axilla in Patients with Invasive/In-Situ Breast Cancer
    - Official Statement - Consensus Guideline on the Management of the Axilla in Patients With Invasive/In-Situ Breast Cancer Purpose To outline the management of the axilla for patients with invasive and in-situ breast cancer. Associated ASBrS Guidelines or Quality Measures 1. Performance and Practice Guidelines for Sentinel Lymph Node Biopsy in Breast Cancer Patients – Revised November 25, 2014 2. Performance and Practice Guidelines for Axillary Lymph Node Dissection in Breast Cancer Patients – Approved November 25, 2014 3. Quality Measure: Sentinel Lymph Node Biopsy for Invasive Breast Cancer – Approved November 4, 2010 4. Prior Position Statement: Management of the Axilla in Patients With Invasive Breast Cancer – Approved August 31, 2011 Methods A literature review inclusive of recent randomized controlled trials evaluating the use of sentinel lymph node surgery and axillary lymph node dissection for invasive and in-situ breast cancer as well as the pathologic review of sentinel lymph nodes and indications for axillary radiation was performed. This is not a complete systematic review but rather, a comprehensive review of recent relevant literature. A focused review of non-randomized controlled trials was then performed to develop consensus guidance on management of the axilla in scenarios where randomized controlled trials data is lacking. The ASBrS Research Committee developed a consensus document, which was reviewed and approved by the ASBrS Board of Directors. Summary of Data Reviewed Recommendations Based on Randomized Controlled
    [Show full text]
  • FDG PET for the Diagnosis of Dementia
    PET for Clinicians Christopher C. Rowe MD FRACP Austin Health University of Melbourne PET in dementia is not new but only in recent years, as PET has become more accessible, has a clinical role emerged. Austin Health, Melbourne does 1000 brain PET per year. Parieto-temporal hypometabolism in AD Clinical Diagnosis of AD • Sensitivity 80%, Specificity 70% (Knopfman, Neurology 2001- average of 13 studies with pathological confirmation) i.e. diagnosis requires dementia and only has moderate accuracy Mild Cognitive Impairment (MCI) does not equate to early AD • Only 50% of MCI will progress to AD dementia • 15-20% have other dementias. • 35-40% do not develop dementia. We need biomarkers for early diagnosis of AD and other dementias! New Research Criteria for AD (2007)* • dementia or significant functional impairment is NOT required • clear history of progressive cognitive decline • objective evidence from psychometric tests of episodic memory impairment • characteristic abnormalities in the CSF or in neuroimaging studies (MRI, FDG-PET, Aβ PET) *Dubois B, Feldman HH, Jacova C, et al. Lancet 2007. FDG PET in Alzheimer’s disease Parietotemporal hypometabolism Reiman EM et al. New Engl J Med 1996;334(12):752–758. View in AC-PC plane bottom of frontal lobe and occipital lobe on same horizontal plane in mid sagittal image Prefrontal Primary sensori-motor cortex Parietal Austin & Repatriation Medical Centre Department of Nuclear Medicine & Centre for PET Reading Brain PET Compare: • parietal vs sensori-motor and frontal • posterior cingulate vs
    [Show full text]